Study of AZD3470 for MTAP Deficient Advanced Solid Tumors
This study is testing a new treatment called AZD3470, which is a PRMT5 inhibitor. It's designed for people with advanced or metastatic solid tumors that are MTAP deficient (meaning they have a specific genetic change). AZD3470 will be given alone or in combination with another anti-cancer drug called Datopotamab deruxtecan (Dato-DXd). The main goals are to see how safe AZD3470 is, what dose works best, and if it helps shrink tumors or slow their growth. To join, you must be at least 18 years old and willing to provide tumor tissue samples. The study is currently unclear on its recruitment status, but plans to enroll up to 334 participants.
- Study design
- This is an open-label, multi-center study, meaning both you and your doctors will know which treatment you are receiving. It has a modular design, with different parts evaluating AZD3470 alone or in combination with other drugs.
- What's involved
- You would be asked to provide written informed consent and comply with study procedures. You would also need to provide archival or new tumor tissue for testing.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your progression will be assessed from the date of randomization up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years). Adverse events will be monitored for 28 days after your last dose of study treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
At a glance
Conditions
Where it's being run
21 sites across 14 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- All Modules: Incidence of adverse events (AEs) and serious adverse events (SAEs). To determine the RP2D of AZD3470 as monotherapy and in combination with anticancer agentsFrom time of informed consent to 28 days post last dose of study treatment
Number of participants with AEs and SAEs.
- Module 1: Incidence of dose-limiting toxicities (DLT)From first dose of study treatment until the end of Cycle 1 (each cycle is 21 days)
Incidence of dose-limiting toxicities (DLT) as determined by number of patients with at least 1 dose-limiting toxicity (DLT)
- Module 2: Progression Free Survival assessed by the Investigator according to RECIST v1.1From date of randomization up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years).
PFS - defined as time from date of randomization until progression per RECIST v1.1 as assessed by the Investigator at local site, or death due to any cause.